bLAC - Treatment of Cutaneous Warts in Immune Suppressed, Kidney Transplanted Patients
Status:
Unknown status
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
As many as 85 % of renal transplant patients may suffer from viral warts with a high degree
of treatment resistance. Promising results of hLAC (human lactalbumin complex with lipid)
point to a beneficial effect without noticeable side effects of bLAC (bovine lactalbumin
complex with lipid). The aim of first clinical trial with bLAC is to show proof of concept in
treatment of cutaneous wart lesions on hands and/or feet after local administration of bLAC
in two dose groups to immune suppressed, kidney transplanted patients.